Why calcium dyshomeostasis may be one of the earliest and most actionable drivers of neurodegeneration
Alzheimer’s disease is usually described through two classic hallmarks: amyloid beta plaques and tau tangles. But there’s a third mechanism that keeps showing up earlier than most people realize, and it may quietly shape how the disease starts, accelerates, and spreads: calcium signaling going off balance.
Calcium ions are not “just minerals.” In the brain, Ca²⁺ acts like a master signal that helps neurons decide when to fire, how strongly synapses should connect, which genes should turn on, and whether a cell can stay alive under stress. In healthy neurons, calcium is tightly controlled by channels on the cell membrane, release gates on the endoplasmic reticulum, and multiple pumps and exchangers that keep intracellular calcium within a safe range. The problem is, Alzheimer’s doesn’t simply damage the brain at the end stage. It pushes this calcium control system out of range early, and once that happens, the neuron starts operating in a toxic environment that slowly becomes impossible to stabilize.
A major trigger is amyloid beta, especially in its oligomer form. These toxic assemblies can disrupt the membrane and overstimulate key calcium entry routes, including receptors and voltage-gated calcium channels. That means calcium begins flooding into the cytosol more than it should. But it doesn’t stop there. The endoplasmic reticulum, which normally stores calcium like a controlled reservoir, can also release excessive calcium through channels such as ryanodine receptors and IP3 receptors. Once calcium rises in these microdomains, the mitochondria often get pulled into the chaos. Calcium is taken up into mitochondria and can overload their capacity, disrupting energy metabolism and accelerating neuronal damage. So instead of calcium supporting memory and synaptic plasticity, it becomes a stress amplifier that pushes neurons toward dysfunction and degeneration.
This is exactly why calcium signaling has become such an attractive but difficult therapeutic target. It’s attractive because calcium dysregulation appears early and connects directly to synaptic failure, mitochondrial dysfunction, and neuronal loss. But it’s difficult because calcium channels and pumps are everywhere in the body. If a compound affects calcium regulation too broadly, it can cause systemic side effects, especially in tissues like the heart and muscle that depend heavily on calcium signaling for normal function. That’s why most Alzheimer’s drug development over the past two decades still leans heavily toward amyloid, tau, and inflammation, with relatively fewer candidates designed to correct calcium signaling directly.
One of the best-known examples of a calcium-related Alzheimer’s therapy is memantine. It is an NMDA receptor antagonist designed to preferentially limit excessive pathological calcium entry while preserving more normal synaptic function. The catch is that its clinical role is mainly symptomatic and typically for moderate to severe disease, which means it doesn’t fully solve the bigger problem: how do we intervene early enough, and precisely enough, to stop calcium imbalance from becoming a self-reinforcing cycle?
This is where newer approaches start to look interesting. The paper discusses research exploring compounds that may reduce amyloid aggregation and stabilize ER-mitochondrial calcium signaling. The concept is simple but powerful: instead of only trying to remove plaques after they form, we reduce the upstream calcium stress that makes neurons fragile in the first place. But the reality is also clear. Any calcium-targeting approach must be selective, controlled, and safe, because the therapeutic window is narrow. Alzheimer’s is not a disease where you can “turn calcium off.” You have to restore balance without breaking normal brain function.
Another major bottleneck in Alzheimer’s treatment is delivery. Even if you have a promising compound, the blood-brain barrier is extremely good at keeping most drugs out. That’s why intranasal delivery has gained attention as a practical strategy, especially for brain-targeting therapies that need faster access and less systemic exposure. Nasal-to-brain delivery leverages the vascularized nasal cavity and can move drugs toward the brain through neuronal pathways such as the olfactory and trigeminal routes. In theory, this provides a more direct path, bypasses first-pass metabolism, reduces dependence on crossing the blood-brain barrier, and may improve the concentration of active drug reaching the brain while lowering off-target risks elsewhere in the body. It’s not perfect. Absorption can vary, nasal tissues can be sensitive, and many approaches are still preclinical. But as a delivery strategy, it’s one of the most realistic “near-term upgrades” to how Alzheimer’s therapies could be deployed, especially for combination treatments that need better brain exposure.
From our perspective, the takeaway is straightforward: Alzheimer’s may not begin with plaques you can see. It may begin with signaling that you can’t see, especially calcium balance quietly shifting into the danger zone. Once calcium regulation breaks, it can connect amyloid toxicity, ER stress, mitochondrial damage, and synaptic decline into a single accelerating loop. That’s why targeting calcium signaling remains challenging, but it also explains why it remains one of the most promising therapeutic directions, especially when paired with smarter delivery methods like intranasal transport and more selective compounds that protect neurons without disrupting the rest of the body.
Source
Song L., Tang Y., Law B. Y. K. (2023). Targeting calcium signaling in Alzheimer’s disease: challenges and promising therapeutic avenues. PMCID: PMC10581553. PMID: 37721273.
